drugset / Trial / NCT03328312

Combined Use of Low-dose Sugammadex Plus Neostigmine Administered for Reversal of Rocuronium

NCT03328312

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Reversal of rocuronium-induced neuromuscular block by the combination of low-doses of neostigmine plus sugammadex decreases the cost of anesthetic medications, while maintaining efficacy of reversal in obese patients.

Timeline

Start
2017-12-01
Primary completion
2018-03-01
Completion
2018-06-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Neostigmine Other / unclassified 0.025 mg/kg
Comparator Neostigmine Other / unclassified 0.05 mg/kg
Comparator Sugammadex Other / unclassified 1 mg/kg
Comparator Sugammadex Other / unclassified 2 mg/kg
Comparator Atropine Other / unclassified 0.5 mg
Comparator Atropine Other / unclassified 1 mg